ctl019

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

The FDA Scheduled to Review Novartis’ Gene Therapy Drug on Wednesday

Novartis AG (NYSE: NVS) is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The U.S. Food and Drug Administration will ask a panel of advisers to focus on the safety of ..